Remibrutinib versus teriflunomide in relapsing multiple sclerosis (REMODEL-1 and REMODEL-2): two randomised, phase 3 trials.

Wiendl H, Bermel R, Airas L, Chitnis T, Nakahara J, Williams M, Adamczyk-Sowa M, Piasecka-Stryczynska K, Zielman R, Dunphy S, et al.